HONG KONG – Swedish biopharma Calliditas Therapeutics AB and Singapore-headquartered pharmaceutical company Everest Medicines II Ltd. agreed to develop and commercialize Nefecon for the treatment of IgA nephropathy in greater China and Singapore in a deal valued at more than $121 million.